Jia-Qi Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jia-Qi Zeng has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Bin Yan
Department of Internal Medicine IV, Heidelberg University Hospital, 69120 Heidelberg, Germany
1 shared publication - Fei Pan
Affiliations School of Medicine, Nankai University, Tianjin, China, Department of Gastroenterology and Hepatology, the First Medical Center, Chinese PLA General Hospital, Beijing, China
1 shared publication - Guanzhou Zhou
School of Medicine, Nankai University
1 shared publication - Ke Meng
Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital, Beijing, China
1 shared publication - Lei Wang
Research Institute of Membrane Separation Technology of Shaanxi Province, Key Laboratory of Membrane Separation of Shaanxi Province, School of Environmental & Municipal Engineering, Xi’an University of Architecture and Technology, Xi’an, China
1 shared publication - Li Li
Teaching and Research Section of Clinical Nursing, Xiangya Hospital, Central South University, Changsha, China
1 shared publication
Latest Publications
- Open Access
- 21 September 2023
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 29 (35) , 5125-5137
Clinical characteristics and outcome of autoimmune pancreatitis based on serum immunoglobulin G4 level: A single-center, retrospective cohort study
Pancreatic ductal adenocarcinoma (PDAC) remains a significant public health challenge and is currently the fourth leading cause of cancer-related mortality in developed countries. Despite advances in cancer treatment, the 5-year survival rate for patients with PDAC remains less than 5%. In recent years, neoadjuvant therapy (NAT) has emerged as a promising treatment option for many cancer types, including locally advanced PDAC, with the potential to improve patient outcomes. To analyze the role of NAT in the setting of locally advanced PDAC over the past decade, a systematic literature search was conducted using PubMed and Web of Science. The results suggest that NAT may reduce the local mass size, promote tumor downstaging, and increase the likelihood of resection. These findings are supported by the latest evidence-based medical literature and the clinical experience of our center. Despite the potential benefits of NAT, there are still challenges that need to be addressed. One such challenge is the lack of consensus on the optimal timing and duration of NAT. Improved criteria for patient selection are needed to further identify PDAC patients likely to respond to NAT. In conclusion, NAT has emerged as a promising treatment option for locally advanced PDAC. However, further research is needed to optimize its use and to better understand the role of NAT in the management of this challenging disease. With continued advances in cancer treatment, there is hope of improving the outcomes of patients with PDAC in the future.
- 21 September 2023
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 29 (35) , 5125-5137
Open AccessClinical characteristics and outcome of autoimmune pancreatitis based on serum immunoglobulin G4 level: A single-center, retrospective cohort study
Pancreatic ductal adenocarcinoma (PDAC) remains a significant public health challenge and is currently the fourth leading cause of cancer-related mortality in developed countries. Despite advances in cancer treatment, the 5-year survival rate for patients with PDAC remains less than 5%. In recent years, neoadjuvant therapy (NAT) has emerged as a promising treatment option for many cancer types, including locally advanced PDAC, with the potential to improve patient outcomes. To analyze the role of NAT in the setting of locally advanced PDAC over the past decade, a systematic literature search was conducted using PubMed and Web of Science. The results suggest that NAT may reduce the local mass size, promote tumor downstaging, and increase the likelihood of resection. These findings are supported by the latest evidence-based medical literature and the clinical experience of our center. Despite the potential benefits of NAT, there are still challenges that need to be addressed. One such challenge is the lack of consensus on the optimal timing and duration of NAT. Improved criteria for patient selection are needed to further identify PDAC patients likely to respond to NAT. In conclusion, NAT has emerged as a promising treatment option for locally advanced PDAC. However, further research is needed to optimize its use and to better understand the role of NAT in the management of this challenging disease. With continued advances in cancer treatment, there is hope of improving the outcomes of patients with PDAC in the future.
- Open Access
- 1 October 2020
- Published by Elsevier in Asian Nursing Research
- Vol. 14 (4) , 241-248
Risk Factors for Work-Related Musculoskeletal Disorders Among Intensive Care Unit Nurses in China: A Structural Equation Model Approach
- 1 October 2020
- Published by Elsevier in Asian Nursing Research
- Vol. 14 (4) , 241-248
Open AccessRisk Factors for Work-Related Musculoskeletal Disorders Among Intensive Care Unit Nurses in China: A Structural Equation Model Approach